6L9.F ViewRay, Inc. XETRA pre-market +2400.00% to €0.03 05 Feb 2026: watch liquidity

The 6L9.F stock moved as a high-volume pre-market mover on XETRA on 05 Feb 2026, rising to €0.03 from a previous close of €0.00 (feed price €0.025). Trading volume hit 3,500.00 shares versus an average of 279.00, giving a relative volume of 12.54 and a price change of 2400.00%. ViewRay, Inc. (6L9.F) is listed on XETRA in Germany and trades in EUR. This sudden activity puts liquidity and execution risk in focus for traders and investors, while fundamentals and sector context remain mixed. We examine why volume spiked and what it means for short-term trading and longer-term outlooks.

Price action and volume spike for 6L9.F stock

Pre-market on 05 Feb 2026 ViewRay, Inc. (6L9.F) recorded a strong move to €0.03 with intraday range €0.00 – €0.03 and volume 3,500.00. The trade volume is more than 12.54x the average daily volume 279.00, marking it as a high-volume mover on XETRA. For active traders, the combination of a low absolute price and thin order books can amplify slippage and spread costs.

Fundamentals snapshot: what the numbers say for ViewRay, Inc. (6L9.F)

ViewRay, Inc. is a US-based medical devices company in MRI-guided radiation therapy; key metrics show market cap €207,228,256.00, EPS -0.55, and PE -0.05. Cash per share is 0.75, book value per share is 0.46, and current ratio is 2.36, indicating liquidity on the balance sheet but ongoing operating losses. Revenue per share is 0.57, and R&D spends near 31.73% of revenue, reflecting continued investment in product development.

Technical context, sector comparison and Meyka grade for 6L9.F stock

Price sits well below the 50-day average €0.32 and 200-day average €2.72, signalling deep short-term weakness versus historical trading levels. The Healthcare sector on XETRA shows modest YTD performance 1.18%, but medical-devices peers typically trade with higher multiples and steadier margins. Meyka AI rates 6L9.F with a score out of 100: 57.47 — Grade C+ (HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst sentiment. The grade is informational and not investment advice.

Risks and catalysts affecting 6L9.F stock

Immediate risk is low liquidity and volatility due to the small float and thin order book; spreads can be wide and orders may move price materially. Company-specific catalysts include product adoption of MRIdian systems, earnings releases, and regulatory updates; the last earnings announcement date on file is 09 May 2024. Macro and sector dynamics in Healthcare and capital spending cycles will also influence demand for ViewRay equipment.

Trading considerations and strategy for high-volume movers like 6L9.F stock

Short-term traders should set limit orders, use small size relative to portfolio, and expect rapid price swings on XETRA. For investors, monitor fundamentals: operating cashflow per share -0.51, free cashflow per share -0.53, and debt-to-equity 1.05, which suggest leverage and negative cash conversion. Check order book depth before executing and consider daylight risk for pre-market fills.

Outlook and model forecast for ViewRay, Inc. (6L9.F stock)

Meyka AI’s forecast model projects a 12-month reference target of €0.08 versus the current feed price €0.025, implying a potential upside of 220.00%. Forecasts are model-based projections and not guarantees. Key drivers to watch are revenue growth from MRIdian installations, margin recovery, and any reduction in R&D intensity relative to sales.

Final Thoughts

Key takeaways on 6L9.F stock: the pre-market move on 05 Feb 2026 made ViewRay, Inc. a high-volume mover on XETRA, with volume 3,500.00 and a relative volume of 12.54. Fundamentals show ongoing losses (EPS -0.55) but reasonable liquidity metrics (current ratio 2.36). Meyka AI’s forecast model projects a 12-month target of €0.08 compared with the current feed price €0.025, an implied upside of 220.00%, while acknowledging the material downside if demand stalls. Traders should prioritise execution controls and size discipline; longer-term investors should wait for clearer revenue and margin inflection. Our analysis and the Meyka grade (C+, HOLD) are informational—forecasts are model-based and not guarantees. For live order book checks and historical trades, see the ViewRay investor site and our Meyka stock page for 6L9.F

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.